EyePoint Pharmaceuticals Stock Price - EYPT

1.21
-0.08 (-6.20%)
Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
EyePoint Pharmaceuticals Inc EYPT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 1.29 0.00 0.00 0.00 1.29 07:41:46
Bid Price Ask Price Spread Spread % News
1.20 1.28 0.08 6.25% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 24 777,572 1.19 - 2.718
Last Trade Time Type Quantity Stock Price Currency
06:51:22 24 $ 1.21 USD

EyePoint Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 139.47M 108.12M $ -44.72M -1.43 - 106.62M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

EyePoint Pharmaceuticals News

Loading Messages....

Latest EYPT Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EYPT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.461.541.251.402,579,000-0.17-11.64%
1 Month1.872.1351.251.54932,849-0.58-31.02%
3 Months1.472.201.251.60657,394-0.18-12.24%
6 Months1.402.691.251.71596,237-0.11-7.86%
1 Year2.582.7181.191.72491,194-1.29-50.0%
3 Years1.783.940.931.83515,508-0.49-27.53%
5 Years4.315.810.932.06363,501-3.02-70.07%

EyePoint Pharmaceuticals Description

EyePoint Pharmaceuticals Inc is a US-based specialty pharmaceutical company which is engaged in developing sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. The company has developed three sustained-release products for the treatment of back-of-the-eye diseases. The lead product candidate is Durasert which is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye for three years from a single injection. The company's development program is focused primarily on utilizing two core technology platforms to deliver drugs and biologics to treat chronic diseases.


Your Recent History
NASDAQ
EYPT
EyePoint P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.